Skip to main content
Equasens logo

Equasens — Investor Relations & Filings

Ticker · EQS ISIN · FR0012882389 LEI · 96950066I7XVFGZI8L92 PA Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 326 across all filing types
Latest filing 2017-02-09 Regulatory Filings
Country FR France
Listing PA EQS

About Equasens

https://equasens.com

Equasens is a company specializing in healthcare IT solutions for professionals and establishments. It develops and provides a range of products including professional software, electronic equipment, connected devices, and digital health solutions. The company's offerings cater to a diverse client base, including pharmacies, hospitals, nursing homes (EHPADs), home care services, and independent medical practitioners. The primary objective of its solutions is to improve the quality of patient care by facilitating the secure sharing of health data, enhancing communication between different care providers, and optimizing the coordination of care pathways across outpatient, hospital, and home care settings.

Recent filings

Filing Released Lang Actions
PHARMAGEST : bilan annuel 2016 du contrat de liquidité
Regulatory Filings Classification · 1% confidence The document is a press release dated February 9, 2017, titled "BILAN ANNUEL DU CONTRAT DE LIQUIDITE CONTRACTE AVEC LA SOCIETE DE BOURSE GILBERT DUPONT" (Annual Statement of the Liquidity Contract with Gilbert Dupont Stock Brokerage Firm). It details the status of the liquidity contract (number of shares and cash balance) as of December 31, 2016, and compares it to the previous semi-annual balance (June 30, 2016). This type of announcement, which reports on specific financial arrangements or regulatory obligations outside of standard periodic reports (like 10-K or IR), fits best under the general category of regulatory announcements or specific financial updates. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it specifically deals with capital management/market operations, it is most closely related to Capital/Financing Update (CAP) or a general Regulatory Filing (RNS). Given the specific nature of reporting on a liquidity contract balance, which is often a requirement related to market making or capital structure maintenance, 'CAP' is a strong candidate. However, since it is a formal, periodic update on a specific financial arrangement often mandated by exchange rules, and it is presented as a 'COMMUNIQUE DE PRESSE' (Press Release), it functions as a specific regulatory disclosure. If 'CAP' is interpreted narrowly as fundraising/financing, this is more about market stability. 'RNS' (Regulatory Filings) is the appropriate fallback for specific, non-core reporting announcements. Given the options, and recognizing this is a specific disclosure about market operations rather than a general financing event, RNS is the safest classification for a specific, non-standard disclosure.
2017-02-09 French
PHARMAGEST INTERACTIVE accélère sa présence en BELGIQUE.
Regulatory Filings Classification · 1% confidence The document is titled 'COMMUNIQUE DE PRESSE' (Press Release) and announces a significant business development: the PHARMAGEST Group's subsidiary SABCO signing a contract with the Belgian pharmacy group MULTIPHARMA to equip 300 pharmacies with software. It details market share changes, partnership terms, and includes a 'Rappel Calendrier financier PHARMAGEST INTERACTIVE' (Reminder of PHARMAGEST INTERACTIVE Financial Calendar) listing future earnings release dates. This content is a strategic business update and announcement, not a formal regulatory filing like a 10-K, a detailed financial report (IR), or a transcript (CT). It fits best as a general business announcement or a specific type of corporate update. Since it is a press release announcing a major commercial agreement and market expansion, it is not a standard 'Earnings Release' (ER) or 'Interim Report' (IR). Given the options, it is a specific corporate announcement. It does not fit perfectly into the defined categories like DIRS, DIV, or CAP. However, it is a significant corporate event announcement. Since it is a press release announcing a major commercial contract and market penetration, it is a general corporate announcement. If a specific category for 'Business Update' or 'Press Release' existed, it would fit there. Lacking that, and since it is not a formal regulatory filing like a 10-K or a specific financial disclosure, the most appropriate fallback, or a category representing general corporate news, is 'Regulatory Filings' (RNS) as a catch-all for non-standard, yet important, public disclosures, or potentially 'Capital/Financing Update' (CAP) if the expansion is viewed as a strategic capital move, but the primary focus is commercial partnership. Given the nature of a press release announcing a major contract, it is most closely aligned with general corporate news dissemination, making RNS the most suitable fallback if a specific 'Press Release' code is unavailable. However, upon re-evaluation, this document is a standard press release announcing a commercial agreement and market share gain, which is often categorized separately. Since there is no 'Press Release' code, and it is not about financing (CAP), management changes (MANG), or dividends (DIV), RNS (Regulatory Filings/Miscellaneous) is the best fit among the provided options for a non-standard, yet public, corporate communication.
2017-01-26 French
PHARMAGEST INTERACTIVE strengthens its presence in Belgium
Regulatory Filings Classification · 1% confidence The document announces a significant business contract win (supply of software to MULTIPHARMA) and provides context on market share changes and subsidiary performance. It also includes key financial dates for upcoming reports (2016 turnover and results). This structure—a press release format detailing operational achievements and strategic updates, rather than a full financial statement or a formal regulatory filing like a 10-K or IR—is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it focuses on operational news and market positioning rather than just the final numbers, and it is not explicitly announcing the *publication* of a report (like an RPA), it fits best as an Earnings Release (ER) which often contains operational highlights preceding the full results, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the content focuses on business development and market share, it strongly resembles the content often included in an ER or a press release accompanying earnings. However, since it is not the formal release of the *results* themselves but rather operational news, and it lists future financial dates, it is most likely a general corporate announcement that doesn't fit the specific financial report codes. Given the options, and the nature of the announcement (a significant business development), it is a strong candidate for a Regulatory Filing (RNS) if it's a mandatory disclosure, or potentially an Earnings Release (ER) if it's a pre-release of operational highlights. Since it is a specific business update, and not a formal financial report, RNS is the safest fallback for a non-standard announcement. However, looking closely at the structure, it reads like a press release detailing operational achievements, which often accompanies or precedes an ER. Since it is not a formal report (10-K, IR) and not explicitly announcing a report (RPA), and it contains strategic business updates, I will classify it as a Regulatory Filing (RNS) as the most appropriate general disclosure category for significant, non-standard news, although it shares characteristics with ER content.
2017-01-26 English
PHARMAGEST acquires start-up SAILENDRA
M&A Activity Classification · 1% confidence The document text describes a corporate action: PHARMAGEST acquiring a majority stake (70%) in the start-up SAILENDRA, which specializes in AI and behavioral analysis. This is a significant business development and change in corporate structure/strategy, involving the acquisition of another company. This falls under the category of M&A Activity (TAR) or potentially Capital/Financing Update (CAP) if it involved a major financing round, but the core event is the takeover/acquisition. Since the definition for M&A Activity (TAR) is 'Announcements and documents related to merger proposals or takeover bids,' this acquisition fits best under TAR. It is not an earnings release (ER), an annual report (10-K), or a general regulatory filing (RNS). The document is detailed and substantive, not a short announcement of a report (RPA).
2017-01-10 English
PHARMAGEST acquiert la start-up SAILENDRA.
M&A Activity Classification · 1% confidence The document announces a significant corporate action: the acquisition of a majority stake (70%) in the start-up SAILENDRA by Groupe PHARMAGEST. This type of announcement, detailing strategic investments, mergers, or acquisitions, falls under the scope of M&A Activity (TAR). Although it contains financial context and mentions future earnings releases, the primary focus and headline news is the takeover/acquisition event itself. It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple regulatory filing (RNS). Therefore, TAR (M&A Activity) is the most appropriate classification.
2017-01-10 French
PHARMAGEST INTERACTIVE : "36 more months at home" initiative scaled up
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and dated November 22, 2016. It announces an initiative scale-up and an award received by the PHARMAGEST Group concerning senior living technology. This format—a brief announcement highlighting key operational news, awards, and business developments, rather than comprehensive financial statements (10-K, IR) or detailed management analysis (MDA)—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is not a formal financial report summary (ER) but rather a specific operational/award announcement, and it doesn't fit other specific categories like Director's Dealing (DIRS) or Capital Change (CAP), it falls best under the general regulatory announcement category, RNS, or potentially ER if the context implies it's an unscheduled release of positive news. Given the structure and focus on a specific project update and award, it functions as a general corporate announcement. However, many press releases announcing operational milestones or awards are often categorized as Regulatory Filings (RNS) if they don't strictly adhere to the format of an Earnings Release (ER) which usually focuses on financial metrics. Since it is a formal announcement from a listed company, RNS is the most appropriate fallback for non-standard, material news.
2016-11-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.